Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

Core Insights - Sionna Therapeutics is focused on developing novel medicines to treat cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein [1][3] - The company will present preclinical data on its NBD1 stabilizers, SION-451 and SION-719, in combination with CFTR modulators, galicaftor (SION-2222) and SION-109, at the European Cystic Fibrosis Conference [1][2] Company Overview - Sionna Therapeutics is a clinical-stage biopharmaceutical company aiming to revolutionize CF treatment through innovative medicines that stabilize CFTR's nucleotide-binding domain 1 (NBD1) [3] - The company is developing a pipeline of small molecules targeting the F508del genetic mutation and complementary CFTR modulators to enhance CFTR function [3] Presentation Details - The oral presentation titled "Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of ΔF508-CFTR" will take place on June 6, 2025 [2] - The presentation will be available on Sionna's website under the "Scientific Presentations" section [2]